These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 35428210)

  • 1. Phase III randomised controlled trial on PSMA PET/CT guided hypofractionated salvage prostate bed radiotherapy of biochemical failure after radical prostatectomy for prostate cancer (PERYTON-trial): study protocol.
    Staal FHE; Janssen J; Brouwer CL; Langendijk JA; Ng Wei Siang K; Schuit E; de Jong IJ; Verzijlbergen JF; Smeenk RJ; Aluwini S
    BMC Cancer; 2022 Apr; 22(1):416. PubMed ID: 35428210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy.
    Roberts MJ; Conduit C; Davis ID; Effeney RM; Williams S; Martin JM; Hofman MS; Hruby G; Eapen R; Gianacas C; Papa N; Lourenço RA; Dhillon HM; Allen R; Fontela A; Kaur B; Emmett L;
    BJU Int; 2024 Feb; 133 Suppl 3():39-47. PubMed ID: 37604702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy.
    Schmidt-Hegemann NS; Fendler WP; Ilhan H; Herlemann A; Buchner A; Stief C; Eze C; Rogowski P; Li M; Bartenstein P; Ganswindt U; Belka C
    Radiat Oncol; 2018 Mar; 13(1):37. PubMed ID: 29499730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Based Clinical Target Volume Delineation Guideline for Postprostatectomy Salvage Radiation Therapy: The PERYTON Guideline.
    Staal FHE; Janssen J; Oprea-Lager DE; Engelen AM; van Limbergen EJ; Smeenk RJ; de Jong MAA; Budiharto TCG; Jacobs I; Haverkort DMAD; Brouwer CL; Ng Wei Siang K; Langendijk JA; Verzijlbergen JF; de Jong IJ; Noordzij W; Aluwini S
    Int J Radiat Oncol Biol Phys; 2024 Mar; 118(3):688-696. PubMed ID: 37729971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HypoFocal SRT Trial: Ultra-hypofractionated focal salvage radiotherapy for isolated prostate bed recurrence after radical prostatectomy; single-arm phase II study; clinical trial protocol.
    Mathier E; Althaus A; Zwahlen D; Lustenberger J; Zamboglou C; De Bari B; Aebersold DM; Guckenberger M; Zilli T; Shelan M
    BMJ Open; 2024 Jan; 14(1):e075846. PubMed ID: 38296279
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Bowden P; See AW; So K; Lawrentschuk N; Moon D; Murphy DG; Rao R; Crosthwaite A; King D; Haxhimolla H; Grummet J; Ruljancich P; Gyomber D; Landau A; Campbell N; Frydenberg M; Smyth LML; Nolan S; Gwini SM; McKenzie DP
    World J Urol; 2021 Nov; 39(11):4117-4125. PubMed ID: 34076753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774).
    Armstrong WR; Kishan AU; Booker KM; Grogan TR; Elashoff D; Lam EC; Clark KJ; Steinberg ML; Fendler WP; Hope TA; Nickols NG; Czernin J; Calais J
    Eur Urol; 2024 Jul; 86(1):52-60. PubMed ID: 38290964
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Calais J; Ceci F; Eiber M; Hope TA; Hofman MS; Rischpler C; Bach-Gansmo T; Nanni C; Savir-Baruch B; Elashoff D; Grogan T; Dahlbom M; Slavik R; Gartmann J; Nguyen K; Lok V; Jadvar H; Kishan AU; Rettig MB; Reiter RE; Fendler WP; Czernin J
    Lancet Oncol; 2019 Sep; 20(9):1286-1294. PubMed ID: 31375469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vesico-urethral anastomosis sampling: a forgotten tool for guiding salvage radiation after radical prostatectomy.
    Timm B; Farag M; Liodakis P; Angus D; Lim Joon D; Bolton D
    BJU Int; 2021 May; 127 Suppl 1():23-29. PubMed ID: 33973332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy.
    Rogowski P; Trapp C; von Bestenbostel R; Eze C; Ganswindt U; Li M; Unterrainer M; Zacherl MJ; Ilhan H; Beyer L; Kretschmer A; Bartenstein P; Stief C; Belka C; Schmidt-Hegemann NS
    Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1417-1428. PubMed ID: 34628521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Machine Learning Approach for Predicting Biochemical Outcome After PSMA-PET-Guided Salvage Radiotherapy in Recurrent Prostate Cancer After Radical Prostatectomy: Retrospective Study.
    Janbain A; Farolfi A; Guenegou-Arnoux A; Romengas L; Scharl S; Fanti S; Serani F; Peeken JC; Katsahian S; Strouthos I; Ferentinos K; Koerber SA; Vogel ME; Combs SE; Vrachimis A; Morganti AG; Spohn SK; Grosu AL; Ceci F; Henkenberens C; Kroeze SG; Guckenberger M; Belka C; Bartenstein P; Hruby G; Emmett L; Omerieh AA; Schmidt-Hegemann NS; Mose L; Aebersold DM; Zamboglou C; Wiegel T; Shelan M
    JMIR Cancer; 2024 Sep; 10():e60323. PubMed ID: 39303279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostatectomy Bed Image-guided Dose-escalated Salvage Radiotherapy (SPIDER): An International Multicenter Retrospective Study.
    Benziane-Ouaritini N; Zilli T; Giraud A; Ingrosso G; Di Staso M; Trippa F; Pommier P; Meyer E; Francolini G; Schick U; Pasquier D; Marc Cosset J; Magne N; Martin E; Gnep K; Renard-Penna R; Anger E; Achard V; Giraud N; Aristei C; Ferrari V; Pasquier C; Zaine H; Osman O; Detti B; Perennec T; Mihoci I; Supiot S; Latorzeff I; Sargos P
    Eur Urol Oncol; 2023 Aug; 6(4):390-398. PubMed ID: 37059627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of a negative PSMA PET/CT in biochemical recurrence of prostate cancer.
    Harsini S; Martineau P; Plaha S; Saprunoff H; Chen C; Bishop J; Tyldesley S; Wilson D; Bénard F
    Cancer Imaging; 2024 Aug; 24(1):117. PubMed ID: 39210431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PSMA PET/CT guided intensification of therapy in patients at risk of advanced prostate cancer (PATRON): a pragmatic phase III randomized controlled trial.
    Ménard C; Young S; Zukotynski K; Hamilton RJ; Bénard F; Yip S; McCabe C; Saad F; Brundage M; Nitulescu R; Bauman G
    BMC Cancer; 2022 Mar; 22(1):251. PubMed ID: 35260100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Site-specific relapse patterns of patients with biochemical recurrence following radical prostatectomy assessed by
    Devos G; Witters M; Moris L; Van den Broeck T; Berghen C; Devlies W; De Meerleer G; Goffin K; Jentjens S; Albersen M; Van Poppel H; Everaerts W; Joniau S
    World J Urol; 2021 Feb; 39(2):399-406. PubMed ID: 32417995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Is Associated with Improved Oncological Outcome in Men Treated with Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer.
    Meijer D; Eppinga WSC; Mohede RM; Vanneste BGL; Meijnen P; Meijer OWM; Daniels LA; van den Bergh RCN; Lont AP; Ettema RH; Oudshoorn FHK; van Leeuwen PJ; van der Poel HG; Donswijk ML; Oprea-Lager DE; Schaake EE; Vis AN
    Eur Urol Oncol; 2022 Apr; 5(2):146-152. PubMed ID: 35074282
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Pfister D; Haidl F; Nestler T; Verburg F; Schmidt M; Wittersheim M; Steib F; Heidenreich A
    BJU Int; 2020 Dec; 126(6):679-683. PubMed ID: 32531840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection rate, pattern of relapse and influence on therapeutic decision of PSMA PET/CT in patients affected by biochemical recurrence after radical prostatectomy, a retrospective case series.
    Francolini G; Detti B; Bottero M; Zilli T; Lancia A; Bruni A; Borghesi S; Mariotti M; Castellucci P; Fanti S; Filippi AR; Teriaca MA; Maragna V; Aristei C; Mazzeo E; Livi L; Ingrosso G
    Clin Transl Oncol; 2021 Feb; 23(2):364-371. PubMed ID: 32602076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml.
    Solomonidou N; Germanou D; Strouthos I; Karagiannis E; Farolfi A; Koerber SA; Debus J; Peeken JC; Vogel ME; Vrachimis A; Spohn SKB; Shelan M; Aebersold D; Grosu AL; Ceci F; Kroeze SGC; Guckenberger M; Fanti S; Belka C; Hruby G; Scharl S; Wiegel T; Bartenstein P; Henkenberens C; Emmett L; Schmidt-Hegemann NS; Ferentinos K; Zamboglou C
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2529-2536. PubMed ID: 36905411
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Calais J; Czernin J; Cao M; Kishan AU; Hegde JV; Shaverdian N; Sandler K; Chu FI; King CR; Steinberg ML; Rauscher I; Schmidt-Hegemann NS; Poeppel T; Hetkamp P; Ceci F; Herrmann K; Fendler WP; Eiber M; Nickols NG
    J Nucl Med; 2018 Feb; 59(2):230-237. PubMed ID: 29123013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.